Bavarian Nordic A/S
CSE:BAVA
Bavarian Nordic A/S
Total Equity
Bavarian Nordic A/S
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Equity
kr11.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
44%
|
CAGR 10-Years
25%
|
|
|
Genmab A/S
CSE:GMAB
|
Total Equity
kr36.7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Equity
kr8.6B
|
CAGR 3-Years
110%
|
CAGR 5-Years
47%
|
CAGR 10-Years
42%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Equity
-€105.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Equity
kr67.8m
|
CAGR 3-Years
14%
|
CAGR 5-Years
22%
|
CAGR 10-Years
9%
|
|
|
Saniona AB
STO:SANION
|
Total Equity
kr231.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
34%
|
CAGR 10-Years
39%
|
|
Bavarian Nordic A/S
Glance View
Bavarian Nordic A/S, established in 1994, is a Danish biotechnology powerhouse distinguishing itself in the development and production of vaccines for infectious diseases and immunotherapies for cancer. The company's journey from a promising start-up to a respected player in the global biotech landscape has been driven by its commitment to innovation and strategic partnerships. Its core operations revolve around a sophisticated platform technology capable of developing vaccines quickly and efficiently. This cutting-edge technology enables Bavarian Nordic to address urgent public health needs, such as growing threats from infectious diseases like smallpox, monkeypox, and Ebola. The company's facility in Kvistgaard is crucial to its operations, allowing it to seamlessly transition from research and development to large-scale production, ensuring a quick response to global health challenges. Revenue generation for Bavarian Nordic is predominantly through contracts and collaborations with governments, health organizations, and pharmaceutical companies. Over the years, the company has secured significant agreements, such as those with the U.S. government for the supply of its smallpox and monkeypox vaccines. These contracts provide a steady income stream, allowing the company to reinvest in its R&D efforts and expand its vaccine pipeline. Moreover, Bavarian Nordic’s strategic acquisitions, like their purchase of Rabipur/RabAvert and Encepur from GlaxoSmithKline, have expanded their portfolio and market presence, providing additional revenue channels. This approach not only sustains the company's growth but also aligns with its long-term vision of addressing unmet medical needs worldwide. By continually leveraging its proprietary technology and expanding its network of strategic collaborations, Bavarian Nordic is well-positioned to advance its mission in the global healthcare arena.
See Also
What is Bavarian Nordic A/S's Total Equity?
Total Equity
11.4B
DKK
Based on the financial report for Dec 31, 2024, Bavarian Nordic A/S's Total Equity amounts to 11.4B DKK.
What is Bavarian Nordic A/S's Total Equity growth rate?
Total Equity CAGR 10Y
25%
Over the last year, the Total Equity growth was 10%. The average annual Total Equity growth rates for Bavarian Nordic A/S have been 16% over the past three years , 44% over the past five years , and 25% over the past ten years .
You don't have any saved screeners yet